Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
2001; Massachusetts Medical Society; Volume: 345; Issue: 15 Linguagem: Inglês
10.1056/nejmoa011110
ISSN1533-4406
AutoresJoseph Keane, Sharon K. Gershon, Robert P. Wise, Elizabeth Mirabile‐Levens, John Kasznica, William D. Schwieterman, Jeffrey Siegel, M. Miles Braun,
Tópico(s)Mycobacterium research and diagnosis
ResumoInfliximab is a humanized antibody against tumor necrosis factor α (TNF-α) that is used in the treatment of Crohn's disease and rheumatoid arthritis. Approximately 147,000 patients throughout the world have received infliximab. Excess TNF-α in association with tuberculosis may cause weight loss and night sweats, yet in animal models it has a protective role in the host response to tuberculosis. There is no direct evidence of a protective role of TNF-α in patients with tuberculosis.
Referência(s)